Analyzing the options chain and the chart patterns of MRTX Mirati Therapeutics prior to the earnings report this week,
I would consider purchasing the 35usd strike price Puts with
an expiration date of 2023-9-15,
for a premium of approximately $0.57.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
Looking...
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib,...
